<!DOCTYPE html>
<html lang="en">
<head><!-- Google Tag Manager --> <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-N4XZHNC');</script> <!-- End Google Tag Manager -->

<title>Apalutamide: Antiandrogen for Castration Resistant Prostate Cancer </title>
  <meta charset="utf-8">
  
  <link href="urology.css" rel="stylesheet">

<meta name="keywords" content="Apalutamide, antiandrogen, androgen receptor blocker, Castration Resistant Prostate Cancer" >
<meta name="description" content="Mechanism, side effects and dosage of apalutamide, an androgen recepter blocker for castration resistant prostate cancer, from the online textbook of urology by D. Manski" >
<meta name="author" content="Dr. med. Dirk Manski" >
<meta name="copyright" content="Dirk Manski" >
<meta name="robots" content="index">
<meta name="robots" content="follow">
<meta name="viewport" content="width=device-width, initial-scale=1">
 </head>

<body><!-- Google Tag Manager (noscript) --> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-N4XZHNC" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <!-- End Google Tag Manager (noscript) --> 
<header>
    <a class="ribbon" tabindex="-1" title="back to start!" href="https://www.urology-textbook.com/index.html">
	   <h5 id="logo">urology-textbook.com</h5>
       <p>Dr. med. Dirk Manski</p>
    </a>  
</header>
<main>
<nav id="navigation">
<ul>
<li><a href="https://www.urology-textbook.com/index.html">Start</a></li>
<li><a href="https://www.urology-textbook.com/anatomy.html">Anatomy</a></li>
<li><a href="https://www.urology-textbook.com/signs-and-symptoms.html">Signs and Symptoms</a></li>
<li><a href="https://www.urology-textbook.com/examinations.html">Examinations</a></li>
<li><a href="https://www.urology-textbook.com/surgical-management.html">Surgical Management</a></li>
<li><a href="https://www.urology-textbook.com/pharmacology.html">Pharmacology</a></li>
<li><a href="https://www.urology-textbook.com/kidneys.html">Kidneys</a></li>
<li><a href="https://www.urology-textbook.com/ureters.html">Ureters</a></li>
<li><a href="https://www.urology-textbook.com/bladder.html">Bladder</a></li>
<li><a href="https://www.urology-textbook.com/prostate.html">Prostate</a></li>
<li><a href="https://www.urology-textbook.com/urethra.html">Urethra</a></li>
<li><a href="https://www.urology-textbook.com/penis.html">Penis</a></li>
<li><a href="https://www.urology-textbook.com/testes.html">Testes</a></li>
<li><a href="https://www.urology-textbook.com/adrenal-glands.html">Adrenal Glands</a></li>
<li><a href="https://www.urology-textbook.com/common-diseases.html">Common Diseases</a></li>
<li><a href="https://www.urology-textbook.com/urologic-surgery.html">Urologic Surgery</a></li>
<li><a href="https://www.urology-textbook.com/index-urology.html">Index</a></li>
<li><a href="https://www.urology-textbook.com/medical-abbreviations.html">Abbreviations</a></li>
<li><a href="https://www.urology-textbook.com/urology-news.html">News</a></li>
<li><a href="https://www.urology-textbook.com/links.html">Links</a></li>
</ul>



 
</nav>
<article>

<p id="brotkrumen">&nbsp;You are here: <a href="https://www.urology-textbook.com/index.html">Urology Textbook</a> &gt; <a href="https://www.urology-textbook.com/pharmacology.html">Drugs in Urology</a> &gt; Apalutamide</p><!-- Main content -->

<h1>Apalutamide: Antiandrogen for Castration Resistant Prostate Cancer</h1>

<h2>Indications for Apalutamide</h2><h3>Castration-resistant non-metastatic prostate cancer (M0 CRPC):</h3> 
<p>Apalutamide is a treatment option for patients with rising PSA levels under androgen deprivation therapy without metastasis in imaging studies (scintigraphy, CT). The approval is limited to patients at high risk: PSA doubling time under 10 months. In the pivotal study (SPARTAN), treatment with apalutamide combined with classic antiandrogen therapy improved metastasis-free survival (41 months vs. 16 months with placebo and hormone therapy). Overall survival was improved with apalutamide, but this was statistically only a trend (Smith et al, NEJM 2018).</p>
<h3>Castration-resistant metastatic prostate cancer (M1 CRPC):</h3> 
<p>Apalutamid is not approved for treatment of M1 CRPC.</p>
<h3>Castration-sensitive metastatic prostate carcinoma (M1 CSPC):</h3> 
<p>Apalutamid is not approved for treatment of M1 CSPC. </p>

<h2>Mechanism of Action of Apalutamide</h2> 

<p>Apalutamide inhibits the <a href="male-hormones-testosterone.html">signal transduction of the androgen receptor</a>: </ p>
<ul title="Effects of Apalutamide">
<li>Competitive inhibition of the androgen binding to the androgen receptor </li>
<li>Prevents translocation of activated receptors to the cell nucleus </li>
<li>Inhibits the binding of the activated androgen receptor to the DNA </li>
</ul>

<h2>Pharmacokinetics of Apalutamide</h2>

<p>100% bioavailability independent from meals, 96% plasma protein binding, hepatic metabolism of apalutamide mainly via CYP2C8 and CYP3A4, half-life 3 days, renal (65%) and fecal excretion of the inactive metabolites. 
</p>

<h2>Side Effects of Apalutamide</h2>

<p>The most common side effects are fatigue (30%) and rash (24% all severity grades and 5% grade 3 or 4). In more than 80% of patients the exanthem improved by dose reduction, systemic corticosteroids or pausing of the medication (see dosage). Further side effects are weight loss (16%), arthralgia (16%), increased risk of falling with fractures (12%), hypothyroidism (8%), epilepsy (&lt;1%).</p>

<h3>Interactions with Apalutamide</h3> 

<p>Apalutamide is a potent enzyme inducer, so caution is recommended with many drug groups such as antiepileptics or oral anticoagulation.</p>

<h2>Contraindications for Apalutamide</h2> 

<ul>
<li>Allergy and intolerance </li>
<li>Women and children </li>
<li>Severe hepatic impairment</li>
</ul>

<h2>Dosage of Apalutamide</h2> 

<p>240 mg apalutamide (four 60&nbsp;mg capsules) p.o. once a day. The addition of prednisolone is not necessary. For rash &geq;grade 3, the medication should be paused to allow recovery. If necessary add local or systemic glucocorticoids. If the rash recurs at re-dosing of 240&nbsp;mg, a dose reduction to 120&ndash;180 mg should be attempted. Discontinue treatment in patients with progressive disease or persistent intolerance to enzalutamide.</p>

<br>
<br><table  id="navigation_unten">
<tr>
 
<td><a href="https://www.urology-textbook.com/enzalutamide.html">Enzalutamide</a></td>
<td><a class="nav4" href="https://www.urology-textbook.com/index-urology.html">Index</a></td>
<td><a class="nav3" href="https://www.urology-textbook.com/cephalosporins.html">Cephalosporins</a></td>
 
</tr>
</table>

<br>
<br>
Index: <a href="https://www.urology-textbook.com/index-urology-a.html">1&ndash;9</a> <a href="https://www.urology-textbook.com/index-urology-a.html">A</a> <a href="https://www.urology-textbook.com/index-urology-b.html">B</a> <a href="https://www.urology-textbook.com/index-urology-c.html">C</a> <a href="https://www.urology-textbook.com/index-urology-d.html">D</a> <a href="https://www.urology-textbook.com/index-urology-e.html">E</a> <a href="https://www.urology-textbook.com/index-urology-f.html">F</a> <a href="https://www.urology-textbook.com/index-urology-g.html">G</a> <a href="https://www.urology-textbook.com/index-urology-h.html">H</a> <a href="https://www.urology-textbook.com/index-urology-i.html">I</a> <a href="https://www.urology-textbook.com/index-urology-j.html">J</a> <a href="https://www.urology-textbook.com/index-urology-k.html">K</a> <a href="https://www.urology-textbook.com/index-urology-l.html">L</a> <a href="https://www.urology-textbook.com/index-urology-m.html">M</a> <a href="https://www.urology-textbook.com/index-urology-n.html">N</a> <a href="https://www.urology-textbook.com/index-urology-o.html">O</a> <a href="https://www.urology-textbook.com/index-urology-p.html">P</a> <a href="https://www.urology-textbook.com/index-urology-q.html">Q</a> <a href="https://www.urology-textbook.com/index-urology-r.html">R</a> <a href="https://www.urology-textbook.com/index-urology-s.html">S</a> <a href="https://www.urology-textbook.com/index-urology-t.html">T</a> <a href="https://www.urology-textbook.com/index-urology-u.html">U</a> <a href="https://www.urology-textbook.com/index-urology-v.html">V</a> <a href="https://www.urology-textbook.com/index-urology-w.html">W</a> <a href="https://www.urology-textbook.com/index-urology-xyz.html">X Y Z</a> 

<br>
<br>
<br>
<hr><h3>References</h3>

<dl>

<dt>Smith, M. R.; Saad, F.; Chowdhury, S.; Oudard, S.; 
    Hadaschik, B. A.; Graff, J. N.; Olmos, D.; Mainwaring, P. N.; Lee, J. Y.; 
    Uemura, H.; Lopez-Gitlitz, A.; Trudel, G. C.; Espina, B. M.; Shu, Y.; 
    Park, Y. C.; Rackoff, W. R.; Yu, M. K.; Small, E. J. &amp; Investigators, S.</dt>
    <dd>Apalutamide 
    Treatment and Metastasis-free Survival in Prostate Cancer.<br><em>The New 
    England journal of medicine, </em><b>2018</b></dd>

</dl>
 

<br>
<br>
<p><img src="https://images.urology-textbook.com/deutsch.gif">&nbsp; Deutsche Version: <a href="https://www.urologielehrbuch.de/apalutamid.html">Apalutamid</a></p>
<br>
</article>
</main>
<footer class="grid">
    <ul id="footer-nav">
    		<li>Copyright by Dr. med. Dirk Manski </li>
		<li><a href="https://www.urology-textbook.com/privacy-policy.html">Privacy policy</a></li>
		<li><a href="https://www.urology-textbook.com/disclaimer.html">Disclaimer</a></li>
	</ul>
</footer>
</body>
</html>
 
